
ROHTO Pharmaceutical Co., Ltd. company was founded by Yasutami Yamada in 1899 as Shintendo Yamada Anmin Pharmacy. Later, it changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical is headquartered in Osaka, Japan. Rohto Pharmaceutical Co., Ltd. engages in the manufacture and marketing of pharmaceutical and other healthcare products in Japan and internationally. It primarily offers eye care, skin care, and oral medicine and supplement products. The company's eye care products include eye drops, eye wash preparations, and contact lens care products. Its eye care products spreads moisture over the surface of the eyes, suppresses allergy and works on ocular itching, as well as are used for the treatment of sties and conjunctivitis, inflammation or itching caused by bacteria on lenses, and eye disease causing pollens and house dust.Rohto company's skin care products include dermal medicines, which are used for the treatment of dry skin and females' anorectal discomforts; lip care products that are used for the prevention of dry, sore, and roughness of lips; and hand, body, sun, and acne care products. Rohto Pharmaceutical's oral medicine and supplement products include `Pansion' brand products, which are primarily used for the treatment of gastric discomfort, mucosal repair agents and stomachics for improving damaged gastric mucosa, stomach pain, and heartburn and other hyperacidity-related symptoms. It also offers a range of test products, including blood sugar testing kits, ovulation self-test kits, and pregnancy self-test kits; and denture cleansers.

Genzyme Biosurgery may turn you into the Six Million Dollar Man, but it can't do anything about your Six Million Dollar Medical Bill. The Genzyme Corp. division develops biotech products for orthopedic procedures. Top sellers include knee osteoarthritis treatment Synvisc and Carticel, which repairs damaged knee cartilage. Genzyme Biosurgery's biosurgical specialties unit makes Seprafilm, which prevents tissue adhesions after surgery. Other products include those to assist in adhesion prevention and hernia repair (Sepramesh) and severe burn treatment (Epicel).

Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, Tennessee. Cumberland Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.

Kent International Holdings, Inc. was founded in 1982 and is based in Far Hills, New Jersey. Kent International Holdings, Inc. (Kent International), formerly Cortech, Inc. was a biopharmaceutical company whose primary focus had been the discovery and development of therapeutics for the treatment of inflammatory disorders. It had directed its research and development efforts principally toward protease inhibitors and bradykinin antagonists. The Company has not identified the particular business, which it will seek to engage, nor has it conducted any market studies with respect to any business or industry to evaluate the possible merits or risks of the target business or industry, which the Company ultimately may operate.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. MAPP company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals.

Intarcia Therapeutics (formerly BioMedicines) sniffs out the competition for its drugs. The development-stage company identifies potential drug candidates in other firms' pipelines, then buys the rights to products it believes can be developed more efficiently or can be effective in treating different indications. Lead drug candidate Atamestane, acquired from Schering AG (now Bayer Schering ), is in clinical trials as a potential treatment for metastatic breast cancer. The company's pipeline also includes omega interferon (purchased from Boehringer Ingelheim), which is being developed to treat hepatitis C; and Biomed 101 (from G.D. Searle), which may have applications for melanoma and kidney cancer.

Opko Health Inc. is a specialty healthcare company. The Company is focused on the discovery, development and commercialization of pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis and management of ophthalmic diseases and conditions. Its business consists of the development of ophthalmic pharmaceuticals and the development, commercialization and sale of ophthalmic diagnostic and imaging systems and instrumentation products. It focuses on exploring opportunities to acquire complementary pharmaceuticals, compounds, and technologies, which could, individually or in the aggregate, materially increase the scale of the Company’s business. On May 6, 2008, the Company completed the acquisition of Vidus Ocular, Inc. (Vidus).

Metabolex, Inc. was founded in 1991 and is based in Hayward, California. Metabolex, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of type II diabetes and related metabolic disorders. The company’s products include MBX-102/JNJ 39659100, an oral small-molecule insulin sensitizer; MBX-8025, which is intended for the treatment of dyslipidemia; MBX-2982, which is an agonist of GPR119, a G-protein coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract; and MBX-2044, a second generation insulin sensitizer.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)






